January 16, 2024

Tarsier Pharma Receives FDA Agreement Under Special Protocol Assessment (SPA) for Tarsier-04 Phase 3 Trial of TRS01 Ophthalmic Solution for the Treatment of Non-infectious Uveitis including Uveitic Glaucoma

June 12, 2023

Tarsier Pharma Announces Publication of Review Article on Suppressing Inflammation for Treating Retinal Blinding Ocular Diseases, Highlighting dazdotuftide (TRS) as a Promising Therapeutic Candidate

16 August, 2022

Tarsier Pharma announces development of TRS02, a potential immunomodulator, for the treatment of retinal diseases with sustained-release intravitreal formulation

21 March, 2022

Bridging the Gender Gap in Scientific Innovation: Tarsier’s CEO, Dr. Daphne Haim-Langford, is interviewed in Oppenheimer’s “Let’s Talk Future™” podcast about women in scientific innovation

Scroll to Top